BRIEF-Cynapsus announces positive phase 3 results for Parkinson's drug

Mon Jul 18, 2016 4:33pm EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

July 18 (Reuters) - Cynapsus Therapeutics Inc

* Top-Line CTH-300 results expected in late Q3 or early Q4

* New drug application for CTH-300 and CTH-301 with FDA expected to be submitted in first half of 2017.

* Cynapsus Therapeutics announces positive phase 3 dose titration phase results with APL-130277 for the treatment of off episodes in patients with Parkinson's disease

* APL-130277 was well tolerated Source text for Eikon: Further company coverage: